



India emerging drug R&D hubPosted AtSify.comIndia is gearing to become a large pharmaceutical
research and development (R&D) destination, with multinational
companies such as Merck and Eli Lilly moving projects
to India and domestic companies such as GVK Biosciences
and Jubilant Organosys investing in providing related
services.Speaking to Business Line on the sidelines
of the World Economic Forum, D.S. Brar, Chairman, GVK
Biosciences, said: "We are providing R&D services to
20 pharma and seven biotech companies. We have already
set up pharma KPO (knowledge process outsourcing) centres
in Chennai and Delhi. In future, we could enter into
collaborations with other companies in drug discovery
on a risk-reward sharing arrangement." The company has
invested about Rs 60 crore in the business and will
invest an equal amount in the coming months. November 29, 2005
|